Clinical trials: Tamoxifen
Breast Cancer
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- 15-95 (NCT00002784)
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 11 sites in Australia, Switzerland
- Volunteers
- 344 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill…
- Trial name
- NCT00002755
- Testing
- filgrastim, CMF regimen, cyclophosphamide
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 600 people
- Sponsor
- Scottish Cancer Therapy Network
Toxicity From Medication (Endocrine Treatment and Chemotherapy) Given for Breast Cancer Treatment.
Predictive Model of Therapy Outcomes in Breast Cancer Patients
Patients with breast cancer, who are treated with curative intent, have a combination of surgery (excision of the tumor) and a course of medical therapy (chemotherapy or endocrine treatment).
- Trial name
- NCT01563211
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Imperial College London
Hot Flashes, Breast Cancer
Acupuncture for Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.
This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation…
- Conditions
- Hot Flashes, Breast Cancer, Acupuncture
- Trial name
- NCT05460819
- Testing
- Acupuncture treatment
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanjing University of Traditional Chinese Medicine
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Phase II Study of Everolimus Beyond Progression
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT02269670
- Testing
- everolimus, anastrozole, letrozole
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Circulatory; Change
Changes in Breast 3D Ultrasound Measurements Using Toremifene
To investigate if there are detectable changes in volume and circulation in breasts of healthy volunteers using toremifene 20 mg in luteal phase of the menstruation cycle versus nonmedicated cycle.
- Trial name
- NCT01417754
- Testing
- Toremifene
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Satakunta Central Hospital
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with chemotherapy or endocrine therapy in treating patients with breast cancer that does not express the human…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT03554044
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Hot Flashes, Breast Neoplasms
Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen
This study is a randomized, placebo-controlled study of desvenlafaxine versus placebo. The purpose of this study is to determine if desvenlafaxine was effective in decreasing the frequency and severity of hot flashes in breast…
- Trial name
- NCT02819921
- Testing
- Desvenlafaxine succinate 100mg, Desvenlafaxine succinate 50mg
- Where
- 3 sites in South Korea
- Volunteers
- 59 people
- Sponsor
- Seoul National University Hospital
Metastatic Invasive Breast Cancer, Resistant Breast Cancer
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer
The goal of this clinical trial is to learn if neratinib, an FDA-approved oral pan-HER2/3/4 inhibitor, improves disease control for participants with metastatic endocrine-resistant ER+/HER2-negative breast cancer.
- Conditions
- Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
- Trial name
- NCT07729046
- Testing
- Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Breast Cancer
PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Breast cancer is an optimal "model disease" for studying personalized medicine. Breast cancer was the first malignancy for which a predictive factor forecasting response to therapy was identified nearly 50 years ago; the…
- Trial name
- PETREMAC (NCT02624973)
- Testing
- Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
- Where
- 7 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Haukeland University Hospital
Desmoid Type-fibromatosis
Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
This is a prospective study evaluating the activity and the safety of toremifene in patients with primary or recurrent sporadic DTs.
- Trial name
- NCT02353429
- Testing
- Toremifene
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Breast Cancer
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen with or without octreotide may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002864
- Testing
- octreotide acetate, tamoxifen citrate
- Where
- 40 sites in United States, Canada
- Volunteers
- 667 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen.
- Trial name
- IBIS-II DCIS (NCT00072462)
- Testing
- tamoxifen citrate, Anastrozole
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 2,980 people
- Sponsor
- Queen Mary University of London
Endometrial Cancer, Endometrial Hyperplasia
Vibrational Spectroscopy for Endometrial Cancer Diagnosis
The purpose of this study is to investigate the ability of vibrational spectroscopic techniques, Raman spectroscopy and Attenuated Total Reflection - Fourier Transform Infrared spectroscopy (ATR-FTIR), to accurately differentiate…
- Trial name
- SPEED (NCT05026073)
- Testing
- Information about clinical risk factors for endometrial cancer and endometrial hyperplasia, Blood and endometrial tissue sampling, Lymph node sampling
- Where
- United Kingdom
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Nottingham University Hospitals NHS Trust
Early Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer
This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC)…
- Trial name
- FeDeriCa (NCT03493854)
- Testing
- Cyclophosphamide, Doxorubicin, Docetaxel
- Where
- 107 sites in United States, Argentina and 17 more
- Volunteers
- 500 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
The HOBOE study was amended in November 2009, and, after reaching enrollment of the first 500 patients, the study began recruiting premenopausal patients only.
- Trial name
- HOBOE (NCT00412022)
- Testing
- tamoxifen, triptorelin, letrozole
- Where
- 20 sites in Italy
- Volunteers
- 1,294 people
- Sponsor
- National Cancer Institute, Naples
Postmenopausal Osteoporosis, Compliance
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
The purpose of this study was to compare compliance and efficacy of raloxifene and strontium ranelate in a group of women with postmenopausal osteoporosis.
- Trial name
- NCT01544894
- Testing
- Raloxifene, Strontium ranelate
- Where
- Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Valencia
Risk Reduction, Mammographic Density Reduction
Low Dose Tamoxifen for Mammographic Density Reduction
KARISMA2 is a randomized, double-blinded, six-armed placebo controlled study to identify a low dose of tamoxifen, with less side-effects and a density reduction non-inferior to the standard dose of 20 mg.
- Trial name
- KARISMA2 (NCT03346200)
- Testing
- Tamoxifen Oral Tablet
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- Per Hall
Breast Cancer, Breast Cancer, Early-Onset
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%
This study is a window of opportunity clinical trial to evaluate the efficacy of giredestrant (GDC-9545) or tamoxifen in estrogen receptor-positive (ER[+])/human epidermal growth factor receptor 2-negative (HER2[-]) primary…
- Trial name
- EMPRESS (NCT05659563)
- Testing
- Giredestrant, Tamoxifen
- Where
- 18 sites in France, Spain
- Volunteers
- 92 people
- Sponsor
- MedSIR
Breast Cancer, Depression
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline
RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood.
- Conditions
- Breast Cancer, Depression, Hot Flashes, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00667121
- Testing
- citalopram hydrobromide, escitalopram oxalate, gabapentin
- Where
- 6 sites in United States
- Volunteers
- 88 people
- Sponsor
- Mayo Clinic